NASDAQ:ACOR - Acorda Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$28.20 +0.35 (+1.26 %)
(As of 08/19/2018 04:00 PM ET)
Previous Close$28.20
Today's Range$27.45 - $28.50
52-Week Range$16.55 - $36.35
Volume229,677 shs
Average Volume595,989 shs
Market Capitalization$1.28 billion
P/E Ratio27.12
Dividend YieldN/A
Acorda Therapeutics logoAcorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease; an inhaled triptan (zolmitriptan) for acute treatment of migraine by using the ARCUS drug delivery technology; SYN120, which is completed Phase II clinical trial to treat Parkinson's disease-related dementia; and BTT1023 (timolumab) that is in Phase II clinical trial for primary sclerosing cholangitis. Further, it develops rHIgM22, which is in Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaborations and license agreements with Biogen International GmbH; Alkermes plc; Rush-Presbyterian St. Luke's Medical Center; Alkermes, Inc.; Astellas Pharma Europe Ltd.; Canadian Spinal Research Organization; Mayo Foundation for Education and Research; Paion AG; Medarex, Inc.; and Brigham and Women's Hospital, Inc. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.

Receive ACOR News and Ratings via Email

Sign-up to receive the latest news and ratings for ACOR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic


Debt-to-Equity Ratio0.56
Current Ratio4.09
Quick Ratio3.92


Trailing P/E Ratio27.12
Forward P/E Ratio-313.33
P/E GrowthN/A

Sales & Book Value

Annual Sales$588.29 million
Price / Sales2.28
Cash Flow$1.8675 per share
Price / Cash15.10
Book Value$11.12 per share
Price / Book2.54


EPS (Most Recent Fiscal Year)$1.04
Net Income$-223,350,000.00
Net Margins-26.87%
Return on Equity8.19%
Return on Assets3.88%


Outstanding Shares47,480,000
Market Cap$1.28 billion

Acorda Therapeutics (NASDAQ:ACOR) Frequently Asked Questions

What is Acorda Therapeutics' stock symbol?

Acorda Therapeutics trades on the NASDAQ under the ticker symbol "ACOR."

How were Acorda Therapeutics' earnings last quarter?

Acorda Therapeutics Inc (NASDAQ:ACOR) released its quarterly earnings results on Thursday, August, 2nd. The biopharmaceutical company reported $1.40 EPS for the quarter, topping the Zacks' consensus estimate of $0.50 by $0.90. The biopharmaceutical company had revenue of $153.30 million for the quarter, compared to analyst estimates of $138.63 million. Acorda Therapeutics had a positive return on equity of 8.19% and a negative net margin of 26.87%. Acorda Therapeutics's revenue for the quarter was up 10.0% on a year-over-year basis. During the same period in the prior year, the company earned $0.29 EPS. View Acorda Therapeutics' Earnings History.

When is Acorda Therapeutics' next earnings date?

Acorda Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, October, 30th 2018. View Earnings Estimates for Acorda Therapeutics.

What price target have analysts set for ACOR?

13 analysts have issued 1 year price targets for Acorda Therapeutics' shares. Their forecasts range from $13.00 to $37.00. On average, they anticipate Acorda Therapeutics' stock price to reach $22.75 in the next twelve months. This suggests that the stock has a possible downside of 19.3%. View Analyst Price Targets for Acorda Therapeutics.

What is the consensus analysts' recommendation for Acorda Therapeutics?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acorda Therapeutics in the last year. There are currently 1 sell rating, 9 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Acorda Therapeutics.

What are Wall Street analysts saying about Acorda Therapeutics stock?

Here are some recent quotes from research analysts about Acorda Therapeutics stock:
  • 1. HC Wainwright analysts commented, "We continue to expect generic erosion of the AMPYRA franchise in the coming months; however, we would also point out that oral arguments in Acorda’s appeal of the court decision to overturn the longest-lived AMPYRA patents have now been completed and the company continues to await a final decision. In the interim, Acorda has inked a conditional settlement agreement with Mylan N.V. (MYL; not rated) and affiliates over AMPYRA, pursuant to which Mylan would be permitted to market its generic version of Ampyra in the U.S. sometime in 2025 or earlier under certain circumstances. Investors should note that Acorda has also signed interim agreements with Teva Pharmaceutical Industries Ltd. (TEVA; not rated) and Hikma Pharmaceuticals PLC (HKMPY; not rated) concerning their patent litigation relating to AMPYRA." (8/6/2018)
  • 2. According to Zacks Investment Research, "Acorda is presently working on strengthening its Parkinson’s pipeline by focusing on the late stage candidate Inbrija in its portfolio. Inbrija’s NDA is under review in the United States and EU. Acorda boasts a strong pipeline addressing a wide range of disorders. The restructing initiative is also encuraging. The company’s share price has outperformed the industry so far this year. However, the company’s key multiple sclerosis drug Ampyra is expected to face generic competition from mid-2018 in the United States. Hence, Acorda’s dependence on Ampyra to draw major part of its revenues is concerning. Moreover, Inbrija received a refusal-to-file letter from the FDA for NDA for Inbrija last August. This in turn delayed its expected commercial launch, which was anticipated much earlier." (7/3/2018)
  • 3. Cantor Fitzgerald analysts commented, "Not what ACOR stock needed. ACOR announced this morning that an increase in blood monitoring for agranulocytosis is being implemented for subjects in the Phase 3 trial of tozadenant in Parkinson’s disease (PD)." (11/15/2017)

Who are some of Acorda Therapeutics' key competitors?

Who are Acorda Therapeutics' key executives?

Acorda Therapeutics' management team includes the folowing people:
  • Dr. Ron Cohen, Founder, CEO, Pres & Director (Age 62)
  • Mr. David Lawrence, Chief of Bus. Operations & Principal Accounting Officer (Age 60)
  • Ms. Lauren M. Sabella, Chief Commercial Officer (Age 57)
  • Mr. Andrew Asa Hindman, Chief Bus. Officer (Age 45)
  • Dr. Burkhard Blank, Chief Medical Officer (Age 63)

Has Acorda Therapeutics been receiving favorable news coverage?

Press coverage about ACOR stock has been trending somewhat positive recently, according to Accern. The research firm identifies negative and positive news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Acorda Therapeutics earned a media and rumor sentiment score of 0.12 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 47.63 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days. View Recent Headlines for Acorda Therapeutics.

Who are Acorda Therapeutics' major shareholders?

Acorda Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Scopia Capital Management LP (16.08%), Dimensional Fund Advisors LP (6.30%), Renaissance Technologies LLC (1.43%), Millennium Management LLC (1.37%), Spark Investment Management LLC (0.87%) and Schwab Charles Investment Management Inc. (0.70%). Company insiders that own Acorda Therapeutics stock include Andrew A Hindman, Barry E Greene, Burkhard Blank, David Lawrence, Ian F Smith, Jane Wasman, Lauren M Sabella, Lorin Randall, Richard P Batycky, Ron Cohen, Scopia Capital Management Lp and Steven M Rauscher. View Institutional Ownership Trends for Acorda Therapeutics.

Which major investors are selling Acorda Therapeutics stock?

ACOR stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Scopia Capital Management LP, Alambic Investment Management L.P., Dimensional Fund Advisors LP, Spark Investment Management LLC, Millennium Management LLC, Cubist Systematic Strategies LLC and Los Angeles Capital Management & Equity Research Inc.. Company insiders that have sold Acorda Therapeutics company stock in the last year include Andrew A Hindman, Burkhard Blank, David Lawrence, Ian F Smith, Lauren M Sabella, Scopia Capital Management Lp and Steven M Rauscher. View Insider Buying and Selling for Acorda Therapeutics.

Which major investors are buying Acorda Therapeutics stock?

ACOR stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Baker BROS. Advisors LP, Nexthera Capital LP, First Trust Advisors LP, Chicago Equity Partners LLC, Acadian Asset Management LLC, Systematic Financial Management LP and Schwab Charles Investment Management Inc.. Company insiders that have bought Acorda Therapeutics stock in the last two years include Ron Cohen and Scopia Capital Management Lp. View Insider Buying and Selling for Acorda Therapeutics.

How do I buy shares of Acorda Therapeutics?

Shares of ACOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Acorda Therapeutics' stock price today?

One share of ACOR stock can currently be purchased for approximately $28.20.

How big of a company is Acorda Therapeutics?

Acorda Therapeutics has a market capitalization of $1.28 billion and generates $588.29 million in revenue each year. The biopharmaceutical company earns $-223,350,000.00 in net income (profit) each year or $1.04 on an earnings per share basis. Acorda Therapeutics employs 484 workers across the globe.

How can I contact Acorda Therapeutics?

Acorda Therapeutics' mailing address is 420 SAW MILL RIVER ROAD, ARDSLEY NY, 10502. The biopharmaceutical company can be reached via phone at 914-347-4300.

MarketBeat Community Rating for Acorda Therapeutics (NASDAQ ACOR)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  316 (Vote Outperform)
Underperform Votes:  408 (Vote Underperform)
Total Votes:  724
MarketBeat's community ratings are surveys of what our community members think about Acorda Therapeutics and other stocks. Vote "Outperform" if you believe ACOR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACOR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/19/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel